Publication Month: Sep 2022 | Report Code: TIPRE00029750 | No. of Pages: 197 | Category: Biotechnology | Status: Published
Growing consumption of personalized medicines is one of the major factors driving the laboratory animal diet market growth. However, the high cost of laboratory animal diet restrains the growth of the overall market growth.
According to the Food and Drug Administration (FDA), personalized medicine aims to increase benefits and reduce patient risks by targeting prevention and treatment more effectively. The practical application of personalized medicine depends heavily on the availability of rigorous diagnostic tools that allow the optimal selection of therapeutic products to improve patient outcomes.
Personalized medicines are treatments based on the environment, the patient's unique biological makeup, and lifestyle. Companies are focused on introducing new companion diagnostics for various types of cancer. For example, in October 2020, Roche received the US FDA approval for the expanded claims of the Cobas EGFR Mutation Test v2 as (CDx) for treating non-small cell lung cancer (NSCLC). Therefore, the FDA approval of such a new and innovative approach may pave the way for patient identification for personalized medicine.
|Market Size Value in||US$ 3,797.50 Million in 2021|
|Market Size Value by||US$ 5,469.24 Million by 2028|
|Growth rate||CAGR of 5.3% from 2022 to 2028|
|No. of Pages||197|
|No. of Tables||110|
|No. of Charts & Figures||83|
|Historical data available||Yes|
|Segments covered||Diet Type, Animal, Application, and End User|
|Regional scope||North America, Europe, Asia Pacific, Middle East & Africa, South & Central America|
|Country scope||US, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina|
|Report coverage||Revenue forecast, company ranking, competitive landscape, growth factors, and trends|
|Free Sample Copy Available|
Personalized medicines are concepts, practices, or modalities that expressly predict the human response to medicines and diseases based on intraspecific differences. Slight differences in genetic makeup can result in dramatic differences in response to drugs or disease. Researchers help in developing approaches to personalized medicines for many genetic disorders. These personalized medicines sometimes use custom genetic interventions, such as antisense-mediated exon skipping or genome editing, to restore protein function in a mutation-specific manner. In drug discovery and development, mice models have played an essential role by characterizing disease pathophysiology and associated injury mechanisms; identifying drug targets; and evaluating novel therapeutics for toxicity/safety, pharmacokinetics, pharmacodynamics, and efficacy. The selection of a specific model for the testing and development of a particular drug depends on the goal of the thorough study.
The traditional use of animal models in drug discovery establishes and demonstrates nonclinical proof of concept for specific drug molecules' safety, efficacy, and target of interest. Animal models can facilitate the development of personalized medicine approaches. Personalized medicine approaches need to be developed and preclinically tested in relevant cell and mouse models containing the human target sequences. The animal models used for personalized medicine research and drug discovery & development are provided with specific diets so that the animal model will react according to the human environment. Therefore, rising demand for personalized medicines is expected to fuel the growth of the laboratory animal diet market during 2022–2028.
China holds a considerable share in the Asia Pacific laboratory animal diet market. China has access to huge colonies of monkeys and other species. Thus, scientists in the country face less public inspection as compare to Europe and the US. China has become the center of the CRISPR animal kingdom, which is appealing to the researchers. Also, the Chinese government has massive investments in new services and determined research projects. Animal research in the country is regulated and administratively managed according to national and provincial laws, regulations, guidelines, and standards. Laboratory animal science in China has developed rapidly over the past 30 years due to governmental and societal forces, which is encouraging the research projects in the country. According to Institute of Laboratory Animal Sciences (ILAS), China uses roughly 20 million animals, such as mice, dogs, rabbits, and nonhuman primates, in research each year. Thus, increasing biomedical research utilizing laboratory animals is expected to drive the laboratory animal diet market during the forecast period.
Based on diet type, the laboratory animal diet market is segmented into standard diet, irradiated diet, and autoclavable diet. The standard diet segment held the largest share of the market in 2021. The standard diet is formulated to meet broad objectives at all life stages involved in feeding laboratory animals i.e., the nutrients that are in general needed for lab animals are already present in the standard diet. For example, the LabDiet canine diet meets the nutritional requirements of all canine species utilized in a laboratory and supports all life stages, such as growth, maintenance, gestation, and lactation. Further, the University of Alabama at Birmingham published a report in 2022 stating that maintaining animal health is critical intended for research purposes, with good nutrition as a key component of health. Standard diets comprising known ingredients are available for rodents. However, nutritionally complete (or replete) diets are not commercially available for some laboratory species. Therefore, top companies are developing standard animal feeding. For example, Envigo's standard diet comprises relatively undefined agricultural commodities such as grains, grain by-products, concentrated plant protein sources, animal proteins, vitamins, minerals, and fats. Thus, the aforementioned factors are responsible for accelerating the adoption of standard diet, ultimately driving the overall laboratory animal diet market growth.
Companies operating in the laboratory animal diet market adopt the product innovation strategy to meet the evolving customer demands across the world, which also permits them to maintain their brand name in the market.
Envigo; Altromin Spezialfutter GmbH & Co. KG; LabDiet; SAFE; Dyets, Inc.; Special Diet Services; Specialty Feeds; Research Diet Inc.; Bio-Serv; and Krishna Valley Agrotech LLP. Are among the key companies operating in the laboratory animal diet market.